DRUG
Pramlintide acetate
Pramlintide acetate administered by a separate pump
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Enrollment
34
Locations
3
Results
Posted
Publications
1
Study summary
What the protocol is testing.
This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.
Full detailed description
Potentially eligible subjects with Type 1 diabetes mellitus who are treated with with a basal-bolus insulin regimen through multiple daily injections or insulin pump at a total daily insulin dose ≤60 U, will be eligible. Visit 1 is approximately 3-6 weeks prior to randomization. Given some variability in HbA1c and C-peptide assays, re-testing for HbA1c and C-peptide can be performed within 18 days from the initial visit. Visit 2 is approximately 2-5 weeks prior to randomization. Subjects are on lispro insulin throughout study except during Visit 4 and Visit 5, the domicile 24 hr treatment period, when they are switched to regular insulin U-100. Screen failed patients may be re-screened for inclusion in the study, as long as re-screening takes place at least 3 months after the original screening visit. If a subject is re-screened, he/she must continue to meet all inclusion/exclusion criteria. All study procedures of initial Visit 1 must be repeated at the re-screening visit.
Interventions
Treatment arms and agents.
DRUG
Placebo
Placebo administered by separate pump
DRUG
Lispro insulin U-100
Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
DRUG
Regular insulin U-100
Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
Timeline
From registration to results.
First posted
Jul 17, 2015
Study start
Aug 17, 2015
Primary completion
Aug 5, 2016
Study completion
Aug 5, 2016
Results posted
Nov 2, 2018
Registry updated
Nov 2, 2018
Outcomes
What the study measures.
Primary outcomes
Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM)
Time frame · 24 h
24-hour MWG mg/dL, defined as total area under the 24-hour tissue glucose curve obtained with CGM, divided by actual time span in the 24-hour period.
Secondary outcomes
Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Lunch
Time frame · 3 hours
Absolute postprandial plasma glucose AUC was measured for the first 3 hours (AUC0-3h) following lunch based on sample availability. (Sample times: 20 hours \[lunch\], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Dinner
Time frame · 2 hours
Absolute postprandial plasma glucose AUC (AUC0-2h) was measured for the first 2 hours following dinner based on sample availability. (Sample times: 2 hours \[dinner\], 2 hours 45 min, 3 hours, 4 hours).
Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Breakfast
Time frame · 2 hours
Absolute postprandial plasma glucose AUC (AUC0-2h) was measured for the first 2 hours following breakfast based on sample availability. (Sample times: 16 hours \[breakfast\], 16 hours 45 min, 17 hours, 18 hours).
Efficacy of Pramlintide by Measurement of Incremental 24-hour Tissue Glucose Area Under the Plasma Concentration-time Curve (AUC) Obtained With Continuous Glucose Monitoring (CGM)
Time frame · 24 h
Incremental (i.e., baseline-corrected) area under the 24-hour tissue glucose concentration curve (AUC0-24h) measured by continuous glucose monitoring (CGM) with a pre-test, non-fasting tissue glucose value as baseline. (Sample times: 0, 30 min, 2 hours \[dinner\], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours \[breakfast\], 16 hours 45 min, 17 hours, 18 hours, 20 hours \[lunch\], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC)
Time frame · 24 h
Absolute mean area under the 24-hour plasma glucose concentration curve, measured as total area under the curve (0 to 24 hours). (Sample times: 0, 30 min, 2 hours \[dinner\], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours \[breakfast\], 16 hours 45 min, 17 hours, 18 hours, 20 hours \[lunch\], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC)
Time frame · 24 hours
Incremental (i.e., baseline-corrected) mean area under the 24-hour plasma glucose concentration curve, measured as total area under the curve (0 to 24 hours). (Sample times: 0, 30 min, 2 hours \[dinner\], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours \[breakfast\], 16 hours 45 min, 17 hours, 18 hours, 20 hours \[lunch\], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
Efficacy of Pramlintide Measured by Percent Time Spent in the Range of >70 mg/dL to <180 mg/dL Tissue Glucose Obtained With Continuous Glucose Monitoring (CGM)
Time frame · 24 h
Percent time spent in the normoglycemic range of tissue glucose concentrations between \>70 mg/dL and \<180 mg/dL, measured by CGM. (Sample times: 0, 30 min, 2 hours \[dinner\], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours \[breakfast\], 16 hours 45 min, 17 hours, 18 hours, 20 hours \[lunch\], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC)
Time frame · 24 h
Absolute mean area under the 24-hour plasma glucagon concentration curve, measured as total area under the curve (total AUC0-24). (Sample times: 0, 30 min, 2 hours \[dinner\], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours \[breakfast\], 16 hours 45 min, 17 hours, 18 hours, 20 hours \[lunch\], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC)
Time frame · 24 h
Incremental (i.e., baseline-corrected) mean area under the 24-hour plasma glucagon concentration curve with a pre-test, non-fasting plasma glucagon value as baseline. (Sample times: 0, 30 min, 2 hours \[dinner\], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours \[breakfast\], 16 hours 45 min, 17 hours, 18 hours, 20 hours \[lunch\], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
Fasting Plasma Glucose Concentration
Time frame · 12 hours after dinner meal
Fasting plasma glucose concentration at 0600 hours (6:00 AM)
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures * Female and/or male aged between 18 and 70 years * Must have a prior diagnosis of T1DM * Body mass index (BMI) \<30 kg/m2 * Subjects are not on current treatment with pramlintide (Symlin) and have not received pramlintide during the 6-month period prior to enrollment * Subjects should be willing to consume all of the components of the standardized meals administered during the study * Negative serum pregnancy test for female subjects of childbearing potential * Female subjects of childbearing potential must be 1 year postmenopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study * Male subjects must be surgically sterile or using an acceptable method of contraception for the duration of the study Exclusion Criteria: * Recurrent severe hypoglycemia requiring assistance within 6 months before screening * A history of hypoglycemia unawareness * A confirmed diagnosis of gastroparesis * Has been treated, is currently being treated, or is expected to require or undergo treatment with the following medications: * Any oral antihyperglycemic agent or any other injectable antihyperglycemic agent that is not insulin * Drugs that directly affect GI motility (eg, anticholinergic agents such as atropine) * Drugs that slow the intestinal absorption of nutrients (eg, α-glucosidase inhibitors * A history of gastric surgery (such as gastric banding, Roux- and Y bypass) * Is expected to require or undergo treatment with acetaminophen after enrollment and at any point during the study * Has experienced diabetic ketoacidosis within the last 24 weeks * History of hospitalization within the last 6 months for glycemic control (for both hyperglycemia or hypoglycemia) * Subject has any significant disease or disorder, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate in the study * Any clinically relevant abnormal findings, which, in the opinion of the investigator, may put the subject at risk because of his/her participation in the study. * Pregnancy confirmed by a positive pregnancy test, or otherwise verified. * Breast feeding * Positive hepatitis C virus antibody (HCV Ab), hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibody (anti-Hbc), or human immunodeficiency virus 1/2 antibody (HIV-1/2 Ab) at Screening * History of, or current alcohol or drug abuse * Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate blood during the study * Has had a major surgery or a blood transfusion within 2 months before Visit 1 (screening) * Participation in any clinical study with an investigational drug or new formulation of a marketed drug during the last 1 month prior to Visit 1
Study locations
3 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Research Site
Chula Vista, California, United States
Research Site
Portland, Oregon, United States
Research Site
Chattanooga, Tennessee, United States
Related trials
More studies on Pramlintide.
NCT IDStudyPhase / statusEnrollmentUpdated
Postprandial Regulation of Bone Perfusion in Healthy Individuals
University of Copenhagen · Healthy Adult Participants · Bone Physiology
Not applicable
Not yet recruiting
15
2026-07
Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide
Oregon Health and Science University · Type 1 Diabetes
Not applicable
Completed
33
2026-06
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
Boston University · Alzheimer Disease · Mild Cognitive Impairment
Early Phase 1
Active, not recruiting
57
2026-05
Tailoring Obesity Treatment Trial
Esbjerg Hospital - University Hospital of Southern Denmark · Obesity · Appetite Regulation
Phase 2 / Phase 3
Withdrawn
0
2026-04
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
University Hospital, Gentofte, Copenhagen · Obesity & Overweight
Not applicable
Recruiting
18
2026-04
Hypersensitivity to Amylin in Post-Traumatic Headache
Danish Headache Center · Headache Disorders, Secondary · Brain Diseases
Not applicable
Not yet recruiting
21
2026-01
Amylin-Induced Migraine Attacks Without Aura
Danish Headache Center · Headache Disorders, Primary · Headache Disorders
Not applicable
Not yet recruiting
21
2026-01
A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes
McGill University Health Centre/Research Institute of the McGill University Health Centre · type1diabetes · Diabetes Mellitus, Type 1
Phase 2 / Phase 3
Unknown
30
2024-04
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.